LDL-lowering drugs are widely recommended for the secondary prevention of vascular events in patients who have experienced a stroke or transient ischaemic attack. As a new study illustrates, however, lipid management among this group remains inadequate, possibly placing patients at unnecessary risk of stroke recurrence.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kernan, W. N. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45, 2160–2236 (2014).
Amarenco, P. et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38, 3198–3204 (2007).
Ovbiagele, B. et al. Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology 66, 1164–1170 (2006).
Saposnik, G. et al. Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get With The Guidelines-Stroke 2003 to 2012. Stroke 45, 3343–3351 (2014).
Stone, N. J. et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (25 Suppl. 2), S1–S45 (2014).
Wolf, P. A. et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 30, 1991–1994 (1999).
Bushnell, C. D. et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 77, 1182–1190 (2011).
Béjot, Y. et al. Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications. J. Neurol. Neurosurg. Psychiatry 84, 348–353 (2013).
Ovbiagele, B. et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke 41, 1508–1513 (2010).
McAlister, F. A. et al. Case management for blood pressure and lipid level control after minor stroke: PREVENTION randomized controlled trial. CMAJ 186, 577–584 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Park, JH., Ovbiagele, B. LDL and stroke risk—clinical practice or target practice?. Nat Rev Neurol 11, 8–9 (2015). https://doi.org/10.1038/nrneurol.2014.234
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2014.234
